Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
NCT03647358Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2018
- Primary completion
- Aug 2027
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Iodine-124 in thyroid carcinoma (TC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of individual lesions response at 1 year. Started Aug 2018; status: recruiting.
02
Drugs
Iodine-124
03
Conditions
thyroid carcinoma (TC)
Beyond the preview
Go deeper on NCT03647358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03647358.